The unvetted and highly controversial measure could pass within just weeks of being proposed and outside of the standard ...

We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to ...

LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...

After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...

We recently compiled a list of the Jim Cramer on Nvidia Plus Other Stocks. In this article, we are going to take a look at ...

Uptake of continuous glucose monitoring (CGM) was relatively low among vulnerable diabetes patients in the largest national ...

Midwest School serves students in preschool to 12th grade. However, honor roll is only given to students in sixth grade and ...

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.

KEY TAKEAWAYS Moderna shares surged further Friday, a day after a senior executive made bullish comments at a healthcare ...

There's no cure for this disease, but now there is some hope for people and their families who are battling the illness in ...

The 340B program has received its share of criticisms, largely due to the lack of transparency into covered entities who ...

Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster ...